Evidence map›Paper›PMID 24376005›Full record

ArticleArthritis care & research2014

Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus.

Apinya Lertratanakul, Peggy Wu, Alan R Dyer, George Kondos, Daniel Edmundowicz, James Carr, Rosalind Ramsey-Goldman

Open access · greenAbstract read
In one paragraph

Article in Arthritis care & research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Pathogenesis and treatment of atherosclerosis in lupus.Rheumatic diseases clinics of North America · 2014
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Apinya LertratanakulNorthwestern University Feinberg School of Medicine, Chicago, Illinois.
Peggy Wu
Alan R Dyer
George Kondos
Daniel Edmundowicz
James Carr
Rosalind Ramsey-Goldman
Northwestern University · USTemple University · USUniversity of Illinois Chicago · US

Funding

MULTIDISCIPLINARY CLINICAL AND TRANSLATIONAL SCIENCE (MCTS) PROGRAM (UL1)UL1RR025741 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GREENLAND, PHILIP · 2008 to 2011
$24.7M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) INTENSIVE PHARMACOKINETICS STUDYM01RR000048 · NCRR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ARICETA, GEMA · 1985 to 2007
$21.1M
Study of Lupus Vascular and Bone Longterm EndpointsP60AR048098 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PASCHE, BORIS · 2002 to 2011
$11.4M
Physical Activity Changes & Thersholds: Quality of Life and Outcomes in Knee OAP60AR064464 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SHARMA, LEENA · 2013 to 2017
$4.5M
SUPERANTIGEN INTERACTIONS WITH MHC CLASS II ANTIGENSP60AR030692 · NIAMS · NORTHWESTERN UNIVERSITY · PI CHANG, ROWLAND W · 1986 to 2001
$2.1M
PATIENT-ORIENTED RESEARCH: SYSTEMIC LUPUS ERYTHEMATOSUSK24AR002138 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI RAMSEY-GOLDMAN, ROSALIND · 2000 to 2009
$1.0M
NCRR NIH HHS M01 RR000048NCRR NIH HHS M01-RR00048NCRR NIH HHS UL1 RR025741NCRR NIH HHS UL1RR025741NIAMS NIH HHS K24 AR002138NIAMS NIH HHS K24-AR02318NIAMS NIH HHS P60 AR030692NIAMS NIH HHS P60 AR048098NIAMS NIH HHS P60 AR064464NIAMS NIH HHS P60-AR30692NIAMS NIH HHS T32-AR0761
6 · The paper itself

Abstract

objectiveTo investigate risk factors in subclinical atherosclerosis progression as measured by coronary artery calcium (CAC) and aorta calcium (AC) in women with systemic lupus erythematosus (SLE; cases) and in comparison with a control population.

methodsA cohort of 149 cases and 124 controls participated in the Study of Lupus Vascular and Bone Long-Term Endpoints. Demographic information, cardiovascular and SLE risk factors, and laboratory assessments were collected at an initial visit. CAC and AC were measured by electron beam computed tomography (CT) or multidetector CT at an initial visit and at a followup visit. Logistic regression models were used to identify predictors of progression in CAC and AC; multivariate models were adjusted for age, hypertension, and total cholesterol to high-density lipoprotein ratio.

resultsHigher modified Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) score (odds ratio [OR] 2.15, 95% confidence interval [95% CI] 1.33-3.57), use of a corticosteroid (OR 2.93, 95% CI 1.14-7.86), and use of aspirin (OR 4.23, 95% CI 1.53-11.74) were associated with CAC progression in multivariate models. Presence of SLE (OR 2.64, 95% CI 1.26-5.72), lower C3 (OR 0.54, 95% CI 0.33-0.87), lower C4 (OR 0.49, 95% CI 0.27-0.86), use of a corticosteroid (OR 2.73, 95% CI 1.03-7.64), higher corticosteroid dose (OR 1.77, 95% CI 1.12-3.00), higher lipoprotein(a) (OR 1.80, 95% CI 1.11-2.98), and higher homocysteine (OR 2.06, 95% CI 1.06-4.29) were associated with AC progression in multivariate models.

conclusionHigher disease damage at the first study visit, as measured by the modified SDI, may predict increased risk in CAC progression, whereas higher disease activity at the first study visit, as measured by hypocomplementemia and use of corticosteroids, may predict increased risk in AC progression.

Indexed as

AdultAtherosclerosisCarotid Intima-Media ThicknessDisease ProgressionFemaleHumansLupus Erythematosus, SystemicMiddle AgedRisk Factors

Identifiers

PMID24376005
PMCPMC4069201
OpenAlexW1867361357

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.